Taming The TGF-β Double-Edged Sword for Tumor Suppression, Navigating a Narrow Therapeutic Window for Clinical Translation & Maximizing Therapeutic Potential in IO

The world of TGFβ is at a tipping point within industry, for an explosion of data to come. 

Exploring the wide array of approaches being utilized in pharma, biotech, and academia, the TGFβ for Immuno-Oncology Drug Development Summit is the ONLY industry-led event dedicated exclusively to exploring TGF-beta's role in cancer therapeutics. This 3-day summit is your definitive meeting to delve into the core challenges of this complex target. 

Don't miss out on your chance to deepen your understanding of cell signaling mechanisms, change your view of the tumor microenvironment, and prepare your candidates for the clinic to ensure patient safety.  

Join your peers this year to:

  • Hear from Scholar Rock on the selective inhibition of TGFβ1 activation with SRK-181, their phase 1 candidate  
  • Discover the latest on Bintrafusp Alfa clinical trials from James Gulley at NCI, and Clinical Development from Yan Lan at EMD Serono 
  • Explore the mechanism of action data from Novartis on their anti-transforming growth factor-beta antibody XOMA089 
  • Get involved in Takeda, Scholar Rock, Oncotelic, and Sanofi's debate the best TGF-beta isoform to target, combination vs monotherapy approaches, and the winning therapeutic approach  
  • Contrast Small Molecule vs Antibody approaches to utilizing Integrin Inhibition with presentations from Morphic Therapeutic and Venn Therapeutics  

This online experience will include live Q&A with speakers, audience video discussions, a virtual exhibition, and the ability to privately message and setup calls through the live attendee list.

Click here to learn more about how you’ll experience this event

3 Reasons Why You Should Get Involved

  • Assess how the likes of Takeda, Scholar Rock exploit the potential of TGF-b in immuno-oncology as the next blockbuster drug
  • Navigate the preclinical and clinical challenges and lessons learned from NCI and EMD Serono
  • Meet dozens of industry experts, discuss TGF-b’s opportunities, and understand the different therapeutic approaches from antibodies to small molecules for maximum therapeutic window

World-Class Speaker Faculty

Some of Our Attendees Include:

"This is the first time a TGFβ meeting has focused exclusively on immune suppression and has collected the key players in the field together to discuss the next steps. A meeting like this has been a long time coming.  I believe this meeting provides us all with the potential for collaboration, idea sharing and creative solving problems, which is truly exciting."

CEO Synthis

Proud to Partner With